InvestorsHub Logo
Followers 8
Posts 1891
Boards Moderated 0
Alias Born 05/05/2016

Re: skitahoe post# 32102

Monday, 04/13/2020 4:55:08 PM

Monday, April 13, 2020 4:55:08 PM

Post# of 44784

I believe that all in a trial should get the drug, the control can easily be all the others in similar circumstances,

Absolutely!!! Dismissing "anecdotal" evidence is dismissing simple facts that are obvious if you care to look. We are in a dire emergency, and to insist on the usual bureaucratic slow as molasses double blind clinical trials would be almost criminally stupid.

but I doubt if the FDA and other regulators will treat it that way.

We'll see. Perhaps having a former business executive at the top, who is interested in results (ex. HCQ) will expedite the process.

I do believe, that based on solid evidence of PLX cells having a beneficial effect in moderating the side effects of pneumonia, and now the seemingly good results with Covid patients, we very likely have an important therapeutic tool to offer.

Even if we don't get direct reports from Pluristem, the continued interest of doctors and patients is the sort of "anecdotal" evidence that strongly suggests good results. After all, doctors do talk to each other about what works, especially now.